高级检索
当前位置: 首页 > 详情页

Danggui-Shaoyao-San improves cognitive impairment through inhibiting O-GlcNAc-modification of estrogen α receptor in female db/db mice.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China [2]Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China [3]Laboratory of Experimental Animal, Guangzhou University of Chinese Medicine, Guangzhou, China [4]Department of Neurology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China [5]Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China [6]Postdoctoral Research Station of Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China [7]Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM and Engineering & Technology Research Center for Chinese Materia Medica Quality of Guangdong Province, Guangdong Pharmaceutical University, Guangzhou, China
出处:
ISSN:

关键词: Danggui-shaoyao-san Diabetic encephalopathy Cognitive dysfunction Estrogen alpha receptor (ERα) O-GlcNAcylation

摘要:
The traditional Chinese medicine formula Danggui-Shaoyao-San (DSS) has been reported to show therapeutic effect on dementia.The present study aims to investigate whether DSS treatment could alleviate diabetes-induced cognitive dysfunction, and explores its neuroprotective mechanism on db/db mice.The female db/db mice were randomly divided into model group, DSS low-dose group and DSS high-dose group. Homologous female db/m mice were used as the control group. DSS was intragastric administrated for 15 weeks. Glucose tolerance, insulin tolerance, blood glucose and blood lipid levels were measured. Morris water maze was used to measure spatial learning and memory ability in mice. Nissl staining and Tunel staining were used to measure the changes of brain neurons, and ELISA kits were used to measure levels of inflammatory mediators (PGE2, TXB2 and LTB4). The kits detected oxidative stress (MDA, SOD, CAT, GSH-PX), nitrosative stress (NO, iNOS, TNOS) and glucose metabolism (LDH, PK, HK) levels. Western blot and immunofluorescence detected neurotrophic factors (PSD95, BDNF, NGF and SYN), apoptosis (Bcl-2, Bax, Bcl-xl, Caspase-3) and changes of ERα, O-GlcNAc, OGT, OGA levels.Morris water maze results showed that DSS could improve the learning and memory abilities of female db/db mice. Nissl staining showed that DSS could relieve hippocampal neurons damage of db/db mice. In addition, the serological tests showed that DSS could improve the impaired glucose tolerance and insulin resistance, while reduce hyperlipemia in db/db mice. Besides, DSS treatment increased the activities of SOD, GSH-PX, and CAT, and reduced MDA, NO, iNOs, tNOS, PGE2, TXB2 and LTB4 levels. Western blot and immunofluorescence results of PSD95, BDNF, NGF, and SYN showed that DSS could improve the expressions of neurotrophic factors. Meanwhile, Tunel staning and Western blot (Bcl-2, Bax, Bcl-xl, Caspase-3) results indicated that DSS could reduce neuronal apoptosis. Finally, Western blot (ERα, O-GlcNAc, OGA, and OGT) and immunofluorescence (ERα and O-GlcNAc) results indicated that DSS could increase the levels of ERα and OGA, decrease the levels of O-GlcNAc and OGT.DSS alleviate DE might be related to improve the abnormal O-GlcNAc-modification of ERα.Copyright © 2021 Elsevier B.V. All rights reserved.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 3 区 医学
小类 | 2 区 全科医学与补充医学 2 区 植物科学 3 区 药物化学 3 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 1 区 全科医学与补充医学 1 区 药学 2 区 药物化学 2 区 植物科学
JCR分区:
出版当年[2019]版:
Q1 PLANT SCIENCES Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q2 PHARMACOLOGY & PHARMACY Q2 CHEMISTRY, MEDICINAL
最新[2023]版:
Q1 CHEMISTRY, MEDICINAL Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q1 PHARMACOLOGY & PHARMACY Q1 PLANT SCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China [2]Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China
通讯作者:
通讯机构: [1]Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China [2]Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China [4]Department of Neurology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China [5]Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China [6]Postdoctoral Research Station of Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China [*1]Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2022 今日访问量:0 总访问量:648 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号